Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting.
Kirby AM, Haviland JS, Mackenzie M, Fleming H, Anandadas C, Wickers S, Miles E, Iles N, Bliss JM, Coles CE; PARABLE Trial Management Group. Kirby AM, et al. Clin Oncol (R Coll Radiol). 2023 Jun;35(6):347-350. doi: 10.1016/j.clon.2023.02.015. Epub 2023 Mar 2. Clin Oncol (R Coll Radiol). 2023. PMID: 36933970 No abstract available.
Avelumab in locally advanced or metastatic urothelial carcinoma.
Jackson-Spence F, Szabados B, Toms C, Yang YH, Sng C, Powles T. Jackson-Spence F, et al. Among authors: toms c. Expert Rev Anticancer Ther. 2022 Feb;22(2):135-140. doi: 10.1080/14737140.2022.2028621. Epub 2022 Jan 20. Expert Rev Anticancer Ther. 2022. PMID: 35015593 Review.
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, Khalique S, Tai J, Attygalle A, Vroobel K, Lord CJ, Natrajan R, Bliss J. Banerjee S, et al. Among authors: toms c. Int J Gynecol Cancer. 2021 Nov;31(11):1471-1475. doi: 10.1136/ijgc-2021-002973. Epub 2021 Sep 13. Int J Gynecol Cancer. 2021. PMID: 34518240 Free PMC article.
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A. Sipos O, et al. Among authors: toms c. Ann Oncol. 2021 Jan;32(1):58-65. doi: 10.1016/j.annonc.2020.10.475. Epub 2020 Oct 21. Ann Oncol. 2021. PMID: 33098992 Free PMC article.
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC. Chopra N, et al. Among authors: toms c. Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7. Nat Commun. 2020. PMID: 32471999 Free PMC article. Clinical Trial.
57 results